The raised guidance and strong operational metrics (44% Adj. EBITDA growth, 2.15x leverage) outweigh the minor EPS miss.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 31 $59.71entry
- T+1 · 4mo ago +1.26%α −0.16% · $60.47
- T+5 · 3mo ago +4.56%α +1.04% · $62.43
- T+20 · 3mo ago −0.97%α −3.96% · $59.13
- T+60 · 22d ago −1.39%α −3.85% · $58.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrightSpring Health Services reported Q2 2026 revenue of $3,873M (+23% YoY) and GAAP diluted EPS from continuing ops of $0.39, a -2.1% miss vs consensus of $0.40. However, the company raised full-year 2026 revenue guidance to $15.1B-$15.425B and Adjusted EBITDA guidance to $820M-$845M, signaling strong operational momentum. The EPS miss is minor and overshadowed by the guidance raise, robust 44% Adjusted EBITDA growth, and a $300M debt paydown that reduced leverage to 2.15x, making this a net positive event for the stock.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $3,873M (+23.0% YoY), above consensus of $3.66B
- GAAP diluted EPS from continuing ops $0.39, -2.1% vs consensus $0.40
- Adjusted EBITDA $206M (+44.2% YoY), with full-year guidance raised to $820M-$845M
- Full-year 2026 revenue guidance raised to $15.1B-$15.425B (17-19.5% growth)
- Leverage reduced to 2.15x from 2.27x QoQ, aided by $300M debt paydown
- Gross profit $493M (+31.5% YoY); gross margin improved to 12.7% from 11.9%
- Operating cash flow $43.9M in Q2; FCF not explicitly stated
- Pharmacy Solutions revenue +22% YoY; Provider Services revenue +30% YoY
- Completed secondary offering by KKR affiliates and $60M share repurchase in June 2026
Financial Impact
Revenue beat consensus by ~5.8% ($3,873M vs $3.66B); Adjusted EBITDA guidance raised by ~$25M at midpoint; $300M debt paydown reduces annual interest expense by ~$12M at ~4% rate
Risk Factors
- EPS miss vs consensus could trigger short-term profit-taking
- Dependence on government reimbursement (Medicare/Medicaid) exposes to policy risk
- Integration of Amedisys/LHC branches ($35M Adj. EBITDA contribution) carries execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336665 |
Track record
24 reports on BTSG
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +45.59% at T+60 after the Feb 27, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $71.36 Now $71.37 +0.01% settles Feb 12
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $67.15 Now $71.37 +6.28% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $65.86 Now $71.37 +8.37% settles Feb 3
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $66.89 Now $71.37 +6.70% settles Jan 28
- Oct 30, 202617d ago 8-K Bullish 6/10 No price data
- Oct 30, 202617d ago Press Release Neutral 5/10 Entry $66.89 Now $71.37 +6.70% settles Jan 28
- Oct 20, 202627d ago Institutional Cluster Neutral 3/10 Entry $62.36 Now $71.37 +14.45% settles Jan 19
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $57.26 Now $71.37 +24.64% settles Dec 28
- Aug 6, 202614w ago Institutional Cluster Bullish 6/10 Entry $60.60 to $66.89 Now $71.37 +17.77% ▲ +10.38% +12.05% vs SPY
- Jul 31, 202615w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers